Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714373 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
A Phase 3 study, sponsored by Soleno Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
NCT03714373 is a Phase 3 study that has completed, run by Soleno Therapeutics. The registered enrollment target is 115 participants.
The verdict
NCT03714373, a Phase 3 study, has completed, sponsored by Soleno Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
Study Summary
This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.
Interventions
- DRUG DCCR
- DRUG Placebo for DCCR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03714373
The ClinicalTrials.gov registry entry for NCT03714373 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soleno Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DCCR is the first listed.
NCT03714373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03714373 about?
NCT03714373 is a clinical study titled "Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period". This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.
What is the current status of trial NCT03714373?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2018-10-01. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT03714373?
The interventions under investigation include: DCCR (DRUG), Placebo for DCCR (DRUG).
Who is sponsoring clinical trial NCT03714373?
This trial is sponsored by Soleno Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.